Background: Telmisartan exhibits superior efficacy in controlling 24-h blood pressure (BP) compared with other angiotensin receptor blockers (ARBs). However, data on its cardiovascular effects in patients with hypertension are limited. This study aimed to evaluate the cardiovascular outcomes in patients taking telmisartan compared to those taking other ARBs.
Methods: This multicenter retrospective study used data from the Korea University Medical Center database, built from electronic health records. A total of 19,247 patients taking two or more antihypertensive medications were identified. Patients prescribed telmisartan (telmisartan users) were compared with those prescribed an ARB other than telmisartan (other ARB users). The primary outcome was major adverse cardiac events (MACE), a composite of cardiovascular death, myocardial infarction, stroke, and hospitalizations due to heart failure. The adjusted outcomes were compared using 1:1 propensity score (PS) matching.
Results: Overall, 3,437 (17.9%) patients were telmisartan users. These patients were more likely to be younger and male and less likely to have a history of chronic kidney disease, dialysis, or heart failure. In the PS-matched cohort, BP control was similar in both groups; however, telmisartan users exhibited significantly lower visit-to-visit BP variability. The adjusted 3-year MACE rate was similar between telmisartan users (4.6%) and other ARB users (4.7%, log-rank P = 0.75), with comparable safety profiles.
Conclusions: In real-world practice, telmisartan showed cardiovascular outcomes similar to those of other ARBs in patients with hypertension taking two or more antihypertensive drugs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ajh/hpae012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- Administrative claims databases often lack accurate records of death, leading researchers to mistakenly treat death as just another reason for study withdrawal instead of a critical competing event.
- A study analyzed nearly 35,000 patients over 1, 3, and 5 years, comparing cardiovascular risks between those taking telmisartan and ramipril, finding significant differences in risk estimates affected by how death is treated in the analysis.
- Results showed that as the follow-up time increased and patients' age rose, the disparities between cause-specific and subdistribution cumulative risks grew, emphasizing the need for researchers to consider baseline mortality risk when using incomplete databases.
Three-Year Cardiovascular Outcomes of Telmisartan in Patients With Hypertension: An Electronic Health Record-Based Cohort Study.
Am J Hypertens
May 2024
Division of Cardiology, Department of Internal Medicine, Korea University Guro Hospital, Seoul, Republic of Korea.
Background: Telmisartan exhibits superior efficacy in controlling 24-h blood pressure (BP) compared with other angiotensin receptor blockers (ARBs). However, data on its cardiovascular effects in patients with hypertension are limited. This study aimed to evaluate the cardiovascular outcomes in patients taking telmisartan compared to those taking other ARBs.
View Article and Find Full Text PDFDevelopment and Verification of Time-Series Deep Learning for Drug-Induced Liver Injury Detection in Patients Taking Angiotensin II Receptor Blockers: A Multicenter Distributed Research Network Approach.
Healthc Inform Res
July 2023
Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Korea.
Article Synopsis
- This study aimed to create a deep learning model to predict drug-induced liver injury (DILI) in patients taking angiotensin receptor blockers (ARBs) using data from six hospitals in Korea.
- A retrospective analysis of 10,852 patient records revealed a 1.09% incidence rate of DILI, varying by drug, with valsartan having the highest rate (1.24%) and olmesartan the lowest (0.83%).
- The model's prediction performance was strong, particularly for telmisartan, losartan, and irbesartan, highlighting useful variables like hematocrit and albumin for better clinical decision-making.
Telmisartan use and risk of dementia in type 2 diabetes patients with hypertension: A population-based cohort study.
PLoS Med
July 2021
Department of Neurology, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
Background: Angiotensin receptor blockers (ARBs) may have protective effects against dementia occurrence in patients with hypertension (HTN). However, whether telmisartan, an ARB with peroxisome proliferator-activated receptor γ (PPAR-γ)-modulating effects, has additional benefits compared to other ARBs remains unclear.
Methods And Findings: Between 1997 and 2013, 2,166,944 type 2 diabetes mellitus (T2DM) patients were identified from the National Health Insurance Research Database of Taiwan.
Comprehensive Exploration of Medications That Affect the Bleeding Risk of Oral Anticoagulant Users.
Biol Pharm Bull
November 2021
Faculty of Pharmaceutical Sciences, Tokyo University of Science (TUS).
Oral anticoagulants (OACs) pose a major bleeding risk, which may be increased or decreased by concomitant medications. To explore medications that affect the bleeding risk of OACs, we conducted a nested case-control study including 554 bleeding cases (warfarin, n = 327; direct OACs [DOACs], n = 227) and 1337 non-bleeding controls (warfarin, n = 814; DOACs, n = 523), using a Japanese health insurance database from January 2005 to June 2017. Major bleeding risk associated with exposure to concomitant medications within 30 d of the event/index date was evaluated, and adjusted odds ratios (aORs) were calculated using logistic regression analysis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!